Expert Commentary: Practice-Changing Advances in Type 2 Diabetes

Download All
Learn expert perspectives on pivotal studies of SGLT2 inhibitors in type 2 diabetes, including possible renal protection in those with or without established chronic kidney disease.
Richard E. Pratley, MD

ClinicalThought

Pivotal SGLT2 inhibitor study results demonstrate renoprotective effects in patients with T2D, with and without established chronic kidney disease.

Richard E. Pratley, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: June 21, 2021 Expired: June 20, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue